Phase 3 TME Clinical Trials
47 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 47 trials
Recruiting
Phase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Acute Treatment of Migraine
Pfizer600 enrolled126 locationsNCT04743141
Recruiting
Phase 2Phase 3
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830
Recruiting
Phase 3
Ketamine Augmentation of ECT in Treatment-Resistant Depression
Major Depressive DisorderTreatment Resistant Depression
Università Vita-Salute San Raffaele30 enrolled1 locationNCT07088380
Recruiting
Phase 3
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Engraftment Syndrome
Henry Ford Health System110 enrolled1 locationNCT05509933
Recruiting
Phase 3
Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke
Ischemic StrokeMedium Vessel OcclusionEndovascular Treatment+1 more
Beijing Tiantan Hospital488 enrolled1 locationNCT07357987
Recruiting
Phase 3
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
Head & Neck CancerPostoperative Adjuvant TreatmentHead & Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University370 enrolled1 locationNCT07445048
Recruiting
Phase 3
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA400 enrolled5 locationsNCT07184619
Recruiting
Phase 3
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
Treatment Resistant DepressionRefractory Depression
University of North Carolina, Chapel Hill23 enrolled1 locationNCT06303739
Recruiting
Phase 3
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Maintenance Treatment of Peripheral T-cell Lymphoma
Fudan University136 enrolled1 locationNCT07300514
Recruiting
Phase 2Phase 3
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
TreatmentSurvivalClassical Hodgkin Lymphoma+6 more
Children's Cancer Group, China96 enrolled1 locationNCT06563245
Recruiting
Phase 3
A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty
TreatmentPrecocious PubertyAcupuncture+1 more
Children's Hospital of Fudan University170 enrolled2 locationsNCT06510764
Recruiting
Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
Major Depressive DisorderTreatment Resistant Depression
Weill Medical College of Cornell University348 enrolled2 locationsNCT04041479
Recruiting
Phase 3
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407
Recruiting
Phase 2Phase 3
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
Cancer Treatment-induced Thrombocytopenia
Qilu Pharmaceutical Co., Ltd.235 enrolled2 locationsNCT06456528
Recruiting
Phase 3
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.662 enrolled1 locationNCT07238283
Recruiting
Phase 3
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Major Depressive DisorderTreatment Resistant Depression
Dr. Inge Winter418 enrolled12 locationsNCT05973851
Recruiting
Phase 3
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
HER2-positive Breast CancerEarly Stage Breast CancerAdjuvant Treatment After Trastuzumab+2 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University300 enrolled1 locationNCT05760612
Recruiting
Phase 3
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
Postmenopausal Women With Osteoporosis at High Risk of Fracture
Qilu Pharmaceutical Co., Ltd.278 enrolled1 locationNCT07062978
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
NSCLCAdjuvant Treatment
Allist Pharmaceuticals, Inc.338 enrolled2 locationsNCT07010419
Recruiting
Phase 3
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.880 enrolled1 locationNCT05838066